Article
Treatment response classification of liver metastatic disease evaluated on imaging. Are RECIST unidimensional measurements accurate?
Department of Radiology, University Hospital of Alexandroupolis, Opsikiou 1, 681 00, Alexandroupolis, Greece.
European Radiology (impact factor:
3.22).
03/2009;
19(7):1809-16.
DOI:10.1007/s00330-009-1327-4
pp.1809-16
Source: PubMed
-
Citations (0)
- Cited In (2)
-
Article: Reply to P. Prassopoulos et al.
Journal of Clinical Oncology 10/2009; · 18.37 Impact Factor -
Article: Metastatic disease response to treatment: how many lesions to measure?
Journal of Clinical Oncology 10/2009; 28(5):e81; author reply 82. · 18.37 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
certain disadvantages
chemotherapy
different response category
individual lesions classification
liver metastases undergoing chemotherapy
Measurements
MRI examinations
patients
post-treatment
RECIST
RECIST guidelines
response evaluation criteria
solid tumors
treatment initiation
two methods
two methods stratified patients
unidimensional measurements
volumetric measurements
volumetric techniques